spacer
home > ict > summer 2019 > the landscape of clinical approval
PUBLICATIONS
International Clinical Trials

The Landscape of Clinical Approval





Cell and gene therapies, and other advanced medicinal products, have generated substantial public health interest, and deservedly so. These living drugs have shown remarkable effectiveness against cancer and other life-threatening illnesses, including rare diseases with previously no treatment available. Recent approvals of cell- and gene-based therapies underscore the industry’s conviction that these drugs will have a strong, positive impact on patient health (1-2). At the same time, accelerated approval pathways are placing a heavy onus on drug developers to assure a consistently pure and efficacious product. Sourcing donor material and assuring efficacy are a lot more complicated when a drug comprises living cells and tissues rather than synthetic products. Accelerated approval also puts significant strain on starting material suppliers, especially in the cell therapy space.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the authors


Dominic Clarke PhD has 15-plus years of experience developing enabling solutions for cell therapy and bioprocessing applications. Dominic is the Global Head of Cell Therapy at HemaCare, the leading provider of donor starting material for development and commercial cell and gene therapies, where he is actively engaged with industry experts to ensure the highest quality materials are delivered. Previously, he has held roles as the Global Product Manager for Charter Medical's cell therapy and bioprocessing disposables portfolio, focused on creating flexible closedsystem solutions for early- and late-stage production, and as the Director of Research and Development at BioLife Solutions, developing novel biopreservation media and methods to support extended stability of cells and tissues.



Brad N Taylor PhD is the Global Marketing Director at HemaCare. Brad has 13- plus years of experience in the biotech industry, addressing multiple aspects of drug discovery and preclinical development. Previously, he has held roles as Application Scientist and Product Manager in the In Vivo Imaging division of PerkinElmer, where he worked to bring innovative solutions to market to assist the research community in expediting and streamlining the process of preclinical drug discovery for cancer and other clinical applications in animal models of disease.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement